gene inactivation reports and usage of PARP1/PARP2-precise inhibition applying olaparib counsel that OVA-induced allergic lung inflammation relies on the polymerase PARP1 (27–31). This confounding variable will make interpretations of benefits with broad-spectrum inhibitors such as PJ-34, which only weakly inhibits PARP14, problematic as the cove